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ABSTRACT 
 
Objectives: To evaluate the validity, reliability and responsiveness of EDC using the WOMAC® NRS 3.1 
Index on Motorola V3 mobile phones.  
Methods: Patients with osteoarthritis (OA) undergoing primary unilateral hip or knee joint replacement 
surgery were assessed pre-operatively and 3-4 months post-operatively. Patients completed the WOMAC® 
Index in paper (p-WOMAC®) and electronic (m-WOMAC®) format in random order.   
Results: 24 men and 38 women with hip and knee OA participated and successfully completed the m-
WOMAC® questionnaire. Pearson correlations between the summated total index scores for the p-
WOMAC® and m-WOMAC® pre- and post-surgery were 0.98 and 0.99 (p<0.0001). There was no 
clinically important or statistically significant between-method difference in the adjusted total summated 
scores, pre- and post-surgery (adjusted mean difference = 4.44, p = 0.474 and 1.73, p = 0.781). Internal 
consistency estimates of m-WOMAC® reliability were 0.87 – 0.98. The m-WOMAC® detected clinically 
important, statistically significant (p<0.0001) improvements in pain, stiffness, function and total index 
score.  
Conclusions: Sixty-two patients with hip and knee OA successfully completed EDC by Motorola V3 
mobile phone using the m-WOMAC® NRS3.1 Index; completion times averaging only 1-1.5 minutes 
longer than the p-WOMAC® Index. Data were successfully and securely transmitted from patients in 
Australia to a server in the USA. There was close agreement and no significant differences between m-
WOMAC® and p-WOMAC® scores. This study confirms the validity, reliability and responsiveness of the 
Exco InTouch engineered, Java-based m-WOMAC® Index application. EDC with the m-WOMAC® Index 
provides unique opportunities for using quantitative measurement in clinical research and practice. 
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Health-related information is increasingly being captured using various electronic media as a valid and 
more efficient method of acquiring information than traditional paper-based approaches.[1-14] Mobile 
phones are ubiquitous and increasingly one of the key methods for the general public to send and receive 
information. Indeed there are more active SIM cards in the world than either computer owners or landline 
telephone subscribers.[15] Exploration of this technology, in the context of sending and receiving health-
related information, is both timely and relevant given an estimated 4 billion active SIM cards currently 
worldwide.[16] 
 
 The WOMAC® Osteoarthritis Index is a globalised condition-specific Patient Reported Outcome 
(PRO) measure, available in 86 different language translations [17,18] and validated in Likert,[19,20] 
Visual analogue [19,20] and Numerical rating (NRS) [21-23] scale formats. While often presented in 
paper-format (p-WOMAC®), we have recently reported the results of a pilot study, in which we compared 
an EDC application of the WOMAC® NRS3.1 Index (m-WOMAC®) developed by Exco InTouch, 
Harlow, UK on three different mobile phone brands.[24] The purpose of the current validation study was 
to evaluate the validity, reliability and responsiveness of the m-WOMAC® Index on Motorola V3 phones 
and extend prior experience on the time to completion and patient preference for the m-WOMAC® 
application.  
 
METHODS 
 
Patients and procedures 
Sixty two patients with hip and/or knee OA were enrolled in the validation study of the m-WOMAC® 
Index application. The rationale for using the NRS-scaled version of the WOMAC® Index and the 
developmental history of the research programme are described in our previous publication.[24]  
 
Following confirmation of ethics approval consenting patients were recruited from Brisbane-area 
hospitals. The following criteria were used to identify suitable patients: Inclusion criteria - Male or female 
subjects, 30 to 85 years of age, history of symptomatic knee or hip OA, radiographic evidence of hip or 
knee OA (radiographs graded by the Kellgren and Lawrence (K-L) Scale,[25] scheduled for primary total 
hip or total knee arthroplasty surgery in the next month and willing and able to provide written informed 
consent; Exclusion criteria - History of gout or episodes of pseudogout in the operative joint, prior history 
of rheumatoid arthritis or psoriatic arthritis, undergoing revision surgery, bilateral surgery, and clinically 
significant co-morbidity, other than hand OA, which in the clinician’s judgement might influence pain, 
stiffness or function scores, or preclude use of a mobile phone.  
 
The procedures followed at the pre-surgery assessment were as follows: a) basic disease, demographic 
and surgical information were collected, using a questionnaire-based structured interview, and b) each 
subject then completed the p-WOMAC® and m-WOMAC® in an order determined by a random process. 
The time to completion, using consistent intervals (start and finish) between p-WOMAC® and m-
WOMAC®, was recorded for both versions. Between completing the two different versions, a natural 
break was created, to diminish the potential of memory effects, by showing the patient a 10 minute 
section of a natural history documentary, devoid of any content relating to arthritis, measurement or 
mobile phones.  
 
Prior to m-WOMAC® completion, each patient underwent one-on-one orientation and had the 
opportunity to “test drive” the application and provide their preferred answers. In the orientation, the 
supervisor explained the features and functionalities of the phone, including how to move from question 
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to question forwards and backwards, how to input a response using both the numeric keypad and 
navigation keys, explained how to go back to missed questions, and how to identify the active part of the 
screen. Following orientation, the phone was reset, for the patient’s independent completion of the m-
WOMAC® Index. The supervisor did not influence the patient’s completion of the Index, neither were 
any prior scores available. The m-WOMAC® application automatically calculated the time to completion 
and transmitted the data from Queensland, Australia to the Exco InTouch server in Raleigh, North 
Carolina. The validity of the transmission process had previously been verified using Exco InTouch’s 
standard operating procedure by sending replicate measurements and comparing data sent against data 
received. All data transfer was completely authentic.  For the p-WOMAC®, patients completed the 
questionnaire in black pen, and time to completion was recorded manually. Pre-surgery assessments 
occurred either at CONROD, in hospital or at the patient’s home. 
 
The same procedures for capturing m-WOMAC® and p-WOMAC® data were followed at 3-4 months 
post-surgery assessment. Finally each patient was questioned using closed and open ended questions, 
regarding their experience with the two versions of the WOMAC® Index and their preferred method for 
completing the WOMAC® Index. Post-surgery assessments either occurred at CONROD or at the 
patient’s home. 
 
Statistical methods 
The a priori sample size estimation was based on a score as percentage of total possible score, an 
observed method equivalence within ± 20%, a hypothesized difference of zero, a between method 
correlation of 0.20, and a standard deviation of differences which is 40% of the mean score.  A sample 
size of at least 56 subjects is required to detect equivalence under these circumstances, at the 5% level of 
significance, with 80% power.[26]  62 people were targeted to allow for a possible 10% attrition rate.  
Missing data analysis did not detect any statistically significant differences between the 10 people who 
were lost to post-surgery follow up and those with complete data with respect to sex, age, height, weight, 
duration of disease, joint affected, mobile phone familiarity, and WOMAC® paper and mobile phone 
scores prior to surgery. 
 
To overcome the problem of confounding order and pre-post surgery effects, four sequences for order 
of questionnaire completion by method (mobile or paper) were used: mppm pmmp mpmp pmpm, where 
the first and second pair of letters indicates the order before and after surgery. A randomized block design 
consisting of 4 subjects per block was used to allocate the four combination sequences.  
 
Double data entry of the paper questionnaires into Excel by two people was also checked using 
standard range and logic checks and compared for accuracy using Excel Compare software, Version 2.1. 
These files were then merged with e-data received by Exco InTouch.  
 
A maximum likelihood, mixed models approach [27] was used to analyse the total WOMAC® score 
for pain, stiffness and function as well as the total index score (TIS) and time taken to complete the 
questionnaire. A model was fitted using generalized linear models [28] where subject variability is a 
random effect and occasion of completion is an effect that is nested within the subjects.  Only one person 
had one missing function item which was replaced with their mean function score.  For the WOMAC® 
scores, the model for the subjects included sequence, the joint replaced (hip or knee).  The model for the 
nested effects included pre-post surgery, occasion within pre- and post-surgery and instrument (paper, 
mobile phone).  For the time taken to complete the questionnaire, joint replaced was excluded. Estimated 
mean differences are reported with 95% confidence limits in parentheses. 
  
Mode of delivery preference was compared using a chi-square goodness of fit test to a null hypothesis 
of no preference, using exact methods to calculate the probability of the observed result.  
FINAL DRAFT 30 JULY 2009  
 5
 
A result is significant if p<0.05.  PASW Statistics, Release 17.0.2 was used for all analyses.  
 
RESULTS  
 
Descriptive statistics 
Twenty four men and 38 women participated with an average age of 69 (range = 47-85) and BMI of 31.2 
(range = 21.8-42.40).  They had hip (n = 24) or knee OA (n = 38) that ranged in duration from 0 .7 to 30 
years (mean = 9.0) (table 1) Twenty three patients (37.1%) had concomitant hand OA with mean disease 
duration of 9.5 years (range 0-40).  Kellgren and Lawrence (K-L) radiographic grades (I-IV) were as 
follows: K-L Grade III (27), K-L Grade IV (35). 
 
Of the 62 patients seen pre-op, 71% were seen at home (table1). The mean time of assessment prior to 
and post-surgery was 8.0 days (range = 1-40 days) and 96.3 days (range = 80-138 days), respectively.  
Total joint replacement operations were performed at four different hospitals by 18 orthopaedic surgeons. 
Ten patients were lost to follow up, the reasons being: surgery cancelled/postponed (5); not contactable 
(1); not interested in further follow-up (4).  
 
Delivery modes  
Using the mixed models analysis there were no statistically significant results for sequence of delivery or 
between the two occasions either pre- or post-surgery for all WOMAC® subscales and the TIS. There 
were significantly higher disability scores pre-surgery in patients with hip OA compared to the patients 
with knee OA (estimated mean difference = 17.5, (95% CI 0.67 to 34.5), p = 0.042).  Post-surgery there 
was significantly greater pain in the patients with knee OA compared to patients with hip OA (estimated 
mean difference = 4.9, (95% CI 0.14 to 9.64, p = 0.044).  Descriptive statistics for m-WOMAC® and  p-
WOMAC® pre- and post-surgery are shown in table 2. 
 
Validity 
Ignoring order of completion, Pearson correlations were calculated to verify the strength of 
association between m-WOMAC® and p-WOMAC® scores for all WOMAC® subscales and 
TIS, pre- and post-surgery. All but one correlation were greater than 0.90 (p<0.0001), Using 
mixed models analysis no statistically significant differences were detected between m-
WOMAC® and p-WOMAC® estimated mean scores for all subscales and TIS at any occasion, 
pre- and post- surgery (p>0.15), likewise for method comparisons, pre- and post-surgery, 
using means across the two occasions (p>0.35), (table 3, fig. 1).  Pre and post surgery, least 
square mean differences between m-WOMAC® and p-WOMAC® scores, as a percentage of 
the mean were small, ranging from 1% to 6% (table 3). Least square mean differences on both 
occasions, pre and post surgery, were between -7% and +6% of the total possible score, which 
is within the ±20% used for the sample size calculation based on equivalence. 
 
Reliability 
Reliability of the m-WOMAC® Index was evaluated from average inter-item correlation, using 
Cronbach’s alpha, for pain and function subscales and TIS, pre- and post-surgery. The stiffness subscale 
was not included as it only contains two items.  The m-WOMAC® and p-WOMAC® reliability 
coefficients pre- and post-surgery were as follows: m-WOMAC® (pre-surgery) pain (0.87), function 
(0.96), TIS (0.97); m-WOMAC® (post-surgery) pain (0.93), function (0.97), TIS (0.98); p-WOMAC® 
(pre-surgery) pain (0.84), function (0.96), TIS (0.97); p-WOMAC® (post-surgery) pain (0.90), function 
(0.97), TIS (0.98).  
  
Responsiveness 
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Responsiveness of each mode of delivery was evaluated by comparing post- with pre-operative  scores.  
For each m-WOMAC® and p-WOMAC® subscale and TIS score, estimated mean scores after surgery 
were significantly lower (p<0.0001) than those before surgery (table 3 and table 4). There were no 
statistically significant differences in responsiveness between the m-WOMAC® and p-WOMAC® 
(p>0.60) for the pain, stiffness and function subscales or TIS. 
 
Completion time and mode preference 
Twenty-six patients (41.9%) reported they were regular mobile phone users and 22 (35.5%) regular 
computer users. The mean time to completion pre- and post-surgery for both the m-WOMAC® and p-
WOMAC® was less <5 minutes (table 2). It was estimated that the m-WOMAC® took 1.05(SE = 0.23) 
and 1.59 (SE = 0.25) minutes longer, pre- and post-surgery, than the p-WOMAC® to complete (p<0.001).  
The majority of respondents reported no preference for the m-WOMAC® vs p-WOMAC®(table 5).  Based 
on overall preference ratings, 81% were either indifferent or preferred the m-WOMAC® application. For 
the remaining respondents who selected a preference, there were no significant differences in preference 
between the two modes for any of the three features (table 5).  
 
DISCUSSION  
 
The purpose of this study was to evaluate the validity, reliability and responsiveness of the m-WOMAC® 
NRS3.1 Index supported by the Exco InTouch engineered Java-based midlet on Motorola V3 mobile 
phones, as well as to address issues of practicality and patient preference. The WOMAC® Index has 
previously been validated in both paper and EDC format [19, 20, 23, 29-31] but not on a mobile phone 
application. The current study is unique with respect to EDC by mobile phone in OA outcome 
measurement using the WOMAC® Index. 
 
The validity of an outcome measure can be assessed in different ways. As expected the Pearson 
correlations between the m-WOMAC® and p-WOMAC® for pain, stiffness, function and TIS were very 
high. However, correlation is not a statistic of agreement but of association. The variation in scores is 
therefore of particular importance. A priori we had established threshold limits of ± 20% of the total 
possible score for equivalence. In this study we observed differences of only -7% to 6%. These small 
differences were neither clinically important, nor statistically significant, and, therefore, confirm the 
validity of the m-WOMAC® application.  
 
Reliability can also be assessed in different ways. Cronbach’s alpha is a commonly used estimate of 
internal consistency, and alpha values of ≥0.80 are considered acceptable. In this study we observed alpha 
values of 0.87-0.97 pre-surgery and 0.93-0.98 post-surgery. These values confirm the reliability of the m-
WOMAC® application.  
 
Responsiveness is a quintessential requirement of an evaluative measure for detecting clinical 
improvement or deterioration. The responsiveness of all the three different scaling formats of the 
WOMAC® Index has previously been reported. Nevertheless, it is important to establish the sensitivity to 
change of the m-WOMAC®, particularly given that the width of the NRS scale is 147 mm on the p-
WOMAC® but only 31 mm on the m-WOMAC®. In this study, statistically significant (p<0.0001), 
clinically important improvements of 74% to 93% of the average were detected for m-WOMAC® pain, 
stiffness, function and TIS scores. These analyses confirm the responsiveness of the m-WOMAC® 
application.  
 
All patients successfully completed the m-WOMAC® Index. The slightly longer average time to 
completion for the m-WOMAC® was statistically significant but is considered clinically unimportant, 
given that both forms of the WOMAC® Index were on average completed in <5 minutes. Furthermore, 
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the majority of patients expressed no difference in preference for mode of administration. Overall these 
data support the acceptability and fast time to completion of both the m-WOMAC® and p-WOMAC® 
Indices. In addition the m-WOMAC® application was consistently successful in transmitting the data 
from patients in Australia to the host server in the Exco InTouch environment in North Carolina. 
 
The strengths of this study include random order of presentation (m-WOMAC® vs p-WOMAC®), and 
the involvement of patients diverse in gender, age, BMI, operative joint, concomitant hand OA, and 
familiarity in the use of computers and mobile phones. In particular 3 patients were over age 80, 23 had 
concomitant hand OA, 40 were not computer users and 36 were not mobile phone users. The lack of 
significant order of presentation effects attests to the success of the randomisation process. Finally the use 
of two different Motorola V3 phones, supervision of patient self-completion by two different health 
professionals and diversity in the conditions under which the m-WOMAC® was completed, all might 
have served to reduce the agreement between m-WOMAC® and p-WOMAC® scores. The high levels of 
validity, reliability and responsiveness are noteworthy given the context in which data were acquired. 
Neither advanced age, concomitant hand OA nor lack of prior routine use of computers or mobile phones 
appeared to be an impediment to the successful completion of the m-WOMAC® application. 
 
There are two recognised limitations to the current study. Firstly the ultimate goal of this research is to 
download the application onto the patient’s own phone or provide study patients with a phone on which 
the application has been installed. Given the evolving nature of mobile phones, the ability to tailor the 
application to existing and future phones, necessarily requires ongoing technical expertise. Our capacity 
to address this was previously demonstrated in the pilot study using different mobile phone brands. The 
second limitation relates to patients taking the phone away with them, for completely unsupervised 
completion of the m-WOMAC®. This issue is not addressed by the present study, however, the capacity 
to remotely initiate patient self-completion of the m-WOMAC®, and receive complete data at the host 
server is currently being assessed.   
 
In considering future regulatory applications, the Exco InTouch application has been developed with 
consideration of the FDA 21 CFR Part 11 guidelines.[32] For end users EDC using a reliable, valid and 
responsive outcome measure permits rapid transfer of data from patient to database eliminates the risk of 
transcription error, permits real-time monitoring of the de-identified database by the monitoring 
committee, facilitates quality assurance and can potentially reduce human resource costs in data 
acquisition. EDC also provides opportunities for remote data capture without the need for a clinic visit, 
verification of the identity of the person completing the questionnaire, and the exact time, date and elapse 
time of questionnaire completion.   
 
Although PROs are not frequently used in routine rheumatology OA clinical practice,[33] Electronic 
Patient Reported Outcomes (E-Pro) creates unique opportunities for measurement in clinical practice, 
including capturing data in the patient’s own environment, multi-directional transfer of information and 
integration into patient management systems. Furthermore, in surgical environments, E-Pro may 
contribute to reducing routine follow-up costs for total joint arthroplasty.[34] Patients can provide 
information of a demographic nature or related to their condition or response to medical, allied health or 
surgical treatment, and can be sent information regarding their condition, benchmarked response to 
treatment [35-49] or instructions regarding actions required. When integrated with a data management 
system, the m-WOMAC® Index and the Exco InTouch technology, have the potential to support goal-
setting and shared decision-making in clinical practice. 
 
In summary, this study indicates that the m-WOMAC® Index is valid, reliable, responsive and 
practical. The unique opportunities created by E-Pro using mobile phones merit further investigation in 
clinical research and practice.  
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Table 1 Descriptive statistics  
 
Descriptive Count Percent Mean SD Range 
Male gender 24 38.7 - - - 
Age (years) 62 68.5 8.7 47 -  85 
BMI 58 31.2 5.1 21.8 - 42.4 
Mobile use 26 41.9 - - - 
Computer use 22 35.5 - - - 
Knee/Hip OA duration (years) 61 9.0 7.90 0.67 - 30 
Operative joint   
Knee 38 61.3 - - - 
Hip 24 38.7 - - - 
Kellgren-Lawrence grade    
Grade III 27 43.6 - - - 
Grade IV 35 56.4 - - - 
Hand OA duration (years)  23 37.1 9.5 10.42 0 - 40 
Time to surgery (days) 62 8.0 7.6 1 - 40 
Time from surgery (days) 52 96.3 11.9 80 - 138 
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Table 2 m-WOMAC® and p-WOMAC® completion times and scores pre- and post-surgery 
 
 Pre-surgery (n=62) Post-surgery (n=52) 
m-WOMAC® p-WOMAC® m-WOMAC® p-WOMAC® 
 COMPLETION TIME (minutes) 
Mean 4.95 3.94 4.54 3.07 
Standard 
deviation 
2.23 2.64 1.80 1.91 
Minimum 1.73 1.03 2.30 0.82 
Maximum 12.52 16.30 11.12 10.58 
 WOMAC® Pain Scores (range 0-50)* 
Mean 26.9 26.5 10.5 9.9 
Standard 
deviation 
9.8 9.8 10.0 9.4 
Minimum 8 7 0 0 
Maximum 45 45 38 38 
 WOMAC® Stiffness Scores (range 0-20)* 
Mean 11.3 11.2 5.3 5.7 
Standard 
deviation 
4.5 4.4 4.4 4.6 
Minimum 0 0 0 0 
Maximum 19 18 18 18 
 WOMAC® Function Scores (range 0-170)* 
Mean 101.5 97.9 44.3 42.4 
Standard 
deviation 
35.0 36.2 36.3 36.0 
Minimum 14 13 0 0 
Maximum 156 149 134 132 
 WOMAC® TIS (range 0-240)* 
Mean 139.6 135.6 60.1 58.1 
Standard 
deviation 
47.6 48.1 49.6 48.3 
Minimum 36 38 0 0 
Maximum 217 212 187 182 
 
* Zero represents the best possible score
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Table 3 Least square mean scores (with Standard Errors) and differences between m-WOMAC® and p-
WOMAC® scores pre- and post-surgery 
 
Pre-surgery Post-surgery 
  
m-
WOMAC® 
p-
WOMAC® Difference 
% 
Diffa 
m-
WOMAC®
p-
WOMAC® Difference 
% 
Diffa 
WOMAC® Pain Scores 
27.12 
(1.24) 
26.74
(1.24)
0.37 
(1.20) 
1% 9.90
(1.33)
9.43
(1.33)
0.47 
(1.32) 
5%
WOMAC® Stiffness Scores 
11.40 
(0.57) 
11.26 
(0.57)
0.14 
(0.616) 
1% 5.23 (0.62) 5.55 
(0.62)
-0.32 
(0.68) 
-6%
WOMAC® Function Scores 
103.6 
(4.59) 
100.03 
(4.59)
3.54 
(4.08) 
2% 44.1 (4.90) 42.6 
(4.90)
1.58 
(4.48) 
2%
WOMAC® TIS 
142.1 
(6.18) 
138.0
(6.18)
4.06 
(5.63) 
3% 59.3
(6.60)
57.6
(6.60)
1.73 
(6.18) 
3%
 
a Difference as a percentage of average estimated score. 
 
 
 
Figure 1 m-WOMAC® and p-WOMAC® standardised least square means and standard errors for 
pain, stiffness, function and TIS, pre- and post-surgery. 
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Table 4  Absolute and percentage improvements detected in estimated mean scores by m-WOMAC® and 
p-WOMAC® 
 
 m-WOMAC®   p-WOMAC®  
WOMAC 
scale 
Pre-post surgery 
differencea 
% Impb Pre-post surgery 
differencea 
% Impb 
Pain 17.2 
(1.31) 
63% 17.3 
(1.31) 
65% 
Stiffness 6.2 
(0.67) 
54% 5.7 
(0.67) 
51% 
Function 59.4 
(4.46) 
57% 57.5 
(4.46) 
57% 
TIS 82.8 
(6.15) 
58% 80.5 
(6.15) 
58% 
a All p values <0.0001. 
b Improvement as a percentage of average estimated score pre-surgery. 
 
 
 
Table 5 Preference for mode of delivery for three different phone features. 
 
Feature No difference m-WOMAC® 
preferred 
p-WOMAC® 
preferred 
Comparison  
of mode 
preference 
Ease of instructions 33 (64%) 7 (13%) 12 (23%) χ2=1.32, p=0.36 
Ease of completion 31 (60%) 11 (21%) 10 (19%) χ2=0.05, p>0.99 
Overall  28 (54%) 14 (27%) 10 (19%) χ2=0.67, p=0.54 
 
 
